aTyr Pharma FY2025 cash $80.9M; Phase 3 sarcoidosis study misses primary endpoint

aTYR PHARMA INC

Phase 3 EFZO-FIT missed primary endpoint (corticosteroid dose reduction at week 48), but showed benefit in KSQ-Lung (p=0.0479) and other secondary measures.
Type C FDA meeting scheduled mid-April 2026 to review EFZO-FIT results and determine path forward for efzofitimod in pulmonary sarcoidosis.
Phase 2 EFZO-CONNECT in SSc-ILD on track to complete enrollment in first half 2026; interim data reported Q2 2025.
Year-end 2025 cash position $80.9 million; R&D expenses $60.2 million, G&A $17.6 million for the year.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

aTYR PHARMA INC reported financial results for the year ended December 31, 2025.

Period: the year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 5, 2026, aTyr Pharma, Inc. issued a press release announcing financial results for the year ended December 31, 2025.

View on SEC.gov

19 earnings releases filed in the last 30 days. Browse all earnings releases →

aTYR PHARMA INC filing history →

Source: SEC EDGAR

accession 0001339970-26-000006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.